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THE NEED TO DISTINGUISH BETWEEN TYPES OF
TRUST
While both types of trust may be required for including
(underrepresented) populations in biomedical research, it
is important to distinguish the role of these types of trust:
Vertical trust can help in allowing researchers to use the
participants’ data in biomedical research; horizontal trust
is important to recruit participants in the first place.
Whether the need for both types of trust is only required
for doing research with underrepresented populations is,
however, questionable. For overrepresented groups, these
two types of trust may have been better established. The
historical discrimination, the maltreatment of underrepre-
sented populations, all kinds of implicit biases, and the
lack of suitable communication indicate that ways to incor-
porate both types of trust have not been successfully devel-
oped yet.
The inclusion of a wide variety of participants includ-
ing underrepresented groups becomes even more impor-
tant in the light of precision medicine. Precision medicine
aims to understand the role of genetics, the environment,
and lifestyle for tailoring approaches to prevent or treat
diseases. Precision medicine starts from the idea of diver-
sity, that there are differences between different groups of
people and individuals, between different living environ-
ments, and between different lifestyles that matter for
deciding which treatment works best for individuals or
subgroups. Rightly, research for precision medicine there-
fore needs to be inclusive and also to include genetic data,
biological samples, and other health information of groups
that are currently still underrepresented in biomedical
research. In order to include diverse populations in such
research, both types of trust need to be fostered. This
means that the trust-corroding factors, identified by the
authors of the target article (Kraft et al. 2018), need to be
dealt with, too. These trust-corroding factors will not
solely be tackled by procedural mechanisms such as insti-
tutional oversight and informed consent. The nature of
precision medicine, which starts from the idea of diversity
and individual variability, and which may require open
data sharing, means that the research enterprise will have
to incorporate ways to build horizontal trust, too. Horizon-
tal trust can be build by open, transparent, and accus-
tomed communication, by taking experiences and
expectations of participants seriously, and by including
their values and wishes in the research practice. A possible
way forward for attaining such horizontal trust from
underrepresented groups is by adjusting to the needs,
goals, and values of these groups, by, for example, partici-
patory research. In participatory research these groups are
not simple research subjects, but are actively involved,
communicated with, or even actively shape and co-create
research procedures and goals of research and have influ-
ence on the governance of these trials.
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In the target article, Kraft and colleagues (2018) use the
term “precision medicine” to denote the ongoing shift
towards large-scale, population-based network or so-
called systems approaches in biomedicine. Alternative
language, however, such as “personalized” and
“stratified” medicine, also exists to describe these
approaches. Rather than simply interchangeable terms,
these different labels reflect the existence of multiple ideas
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about what, exactly, systems approaches entail and what
their aims are in relation to health care, in turn based on
different aspirations regarding the future of medicine and
moral and political assumptions about the role and func-
tion of health care systems. The authors’ terminological
choices, both in framing their argument in relation to the
“precision medicine research enterprise” and in the library
metaphor through which they choose to present this
research, thus mirror and implicitly build on wider dis-
courses embedded in the U.S. context. We argue that a
more critical consciousness of the political and socioeco-
nomic context and the discourses mobilized by “precision
medicine” is needed, to make explicit the ethical founda-
tions and underlying values that these terms and practices
reflect.
Systems approaches in medicine have been widely her-
alded as revolutionary in academic and policy discourses.
While “personalized medicine” is the term most widely
used to describe systems approaches and their potential
(Pokorska-Bocci et al. 2014), some have argued that the
term “stratified medicine” more realistically captures what
systems approaches can actually deliver—that is, medicine
based on group stratification rather than personalization.
The language of stratification, however, carries potentially
negative associations with social stratification and racial
profiling (Farrow, Swinn, and Bua 2014). Based on research
with stakeholders, Juengst and colleagues (2016) argued
that the term has failed to gain traction in the United States
in particular due to these associations, which should be
contextualized in relation to American politics of race and
the long history of both racial segregation built on scien-
tific racism, and powerful antiracist political opposition in
response to this. They argue that a rhetorical “rebranding”
has taken place in the United States, moving from the lan-
guage of personalization toward the term “precision medi-
cine,” epitomized by the 2015 launch of the $215 million
Precision Medicine Initiative (PMI) and the “All of Us”
research program (White House 2015). This terminological
“rebranding” both reflects and has implications for the eth-
ical priorities and values that are driving the development
of systems approaches and related research investment in
the US.
“Precision medicine” avoids what the World Health
Organization (WHO) calls the “possibly overambitious”
promise of “personalized medicine” (WHO 2013, 180)
while still enabling policymakers to apply the rhetorical
force of medicine “tailored to individuals’ lifestyles, genes,
environment and preferences” (White House 2015). It
avoids “stratified medicine’s” associations with social
stratification, while reframing the group stratification and
medical profiling that systems approaches enact as ethi-
cally neutral or positive “precision.” It also enables the
joining of genomics (and other -omics fields) with other
ethically complex and controversial research modes
including biobanking and data mining of electronic health
records under the mantle of “precision,” and associations
of the collation of these data-intensive research modes
with notions such as “precision equipment.” It even
resonates with “military precision” and concepts like
“precision bombing” in contemporary American culture
(Juengst et al. 2016).
The choice, in the U.S. context, of “precision medicine”
to describe this form of research thus reflects policy-
makers’ need for public approval for policy initiatives and
investment in systems approaches. It exploits the appeal of
medicine focused on individuals’ needs, and also builds
on public discourses around patient empowerment and
autonomy. In making their argument regarding the impor-
tance of trust to the “precision medicine” research enter-
prise, Kraft and colleagues draw implicitly on these
situated discourses without acknowledging or unpacking
them.
While Kraft and colleagues emphasize trustworthiness
as both an intrinsic ethical and an instrumental value,
strategies applied by proponents of the PMI to attract pub-
lic trust complicate their arguments focused on facilitating
trust in the precision medicine research enterprise. PMI
proponents have mobilized citizenship rhetoric and
appealed to constructs of a shared national identity in
ways reflecting particular cultural values and policy agen-
das of the initiative. The “All of Us” program aims to cor-
relate a wide range of data with health outcomes and
make the results widely accessible, including to “citizen
scientists” and “engaged participants” (National Institutes
of Health [NIH] 2015, 19–20). The aim is to “empower indi-
viduals and families to invest in and manage their health”
by providing them with more “precise” medical informa-
tion to modify their lifestyle and take personal control over
their health (White House 2015).
“Precision medicine” is thus intertwined with empower-
ment discourses that build on models of citizens’ active par-
ticipation in research and health care, where both are
framed around a social contract model of benefits and obli-
gations. The health care benefits to citizens are framed as an
exchange for contributing to research and taking responsibil-
ity over one’s own health. This mirrors broader discourses
around what has been called “responsibilization” in various
health care contexts (Nuffield Council of Bioethics 2010),
whereby rhetoric focused on citizens’ empowerment is
translating into increased individual responsibility over
health and, consequently, a diminished burden of care car-
ried by state and public health authorities.
Like the language of “precision,” emphasis on individ-
ualization carries strong resonance in American culture,
where a liberal individualistic ethos is embedded in the
value system, but it is also combined with nationalistic dis-
courses around “our” shared national interests and values
(as Americans) in ways that appeal to a collective national
identity—“All of Us,” as the core research program is
labelled. “Precision medicine” in the United States is there-
fore neither politically nor ethically neutral, not only as a
choice of language but as the practice of precision medi-
cine itself—the entire “research enterprise.” If we are to
trust in this enterprise, we need to enquire further as to the
implicit values of the system in which we are being asked
to trust.
Relationships With Populations in Precision Medicine Research
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Relatedly, Kraft and colleagues seem to presume that
research initiatives like the PMI and associated databanks
are “a public good,” as the library metaphor implies.
They state that this metaphor was chosen because
it seemed to invoke “minimal biases,” while the term
“biobank” elicited “potentially misleading” analogies and
“confusion” including associations with financial banks
and gold mines. Yet the library metaphor, deliberately
selected to avoid negative connotations, is still non-neu-
tral: It has the opposite effect of invoking positive associa-
tions and thus carries its own bias.
In fact, the realities of the U.S. health care system
throw into question the extent to which research pro-
grams like the PMI are, indeed, a “public good,” under-
mining the empirical accuracy of Kraft and colleagues’
presumption that the associations invoked by the alter-
native term “biobank” necessarily imply confusion or
are misleading. Unlike in most high-income countries
where public health care systems are built on welfare
models, including the assumption that benefits from
national research efforts should be equitably distributed
to citizens, the U.S. health care system is disproportion-
ately structured by a private and employment-based
health insurance model. Health care is not similarly
considered a basic right, nor can national research ini-
tiatives be uncritically assumed to be “a public good,”
the benefits of which would be distributed to “the pub-
lic” based on equitable principles of access. Rather,
despite proponents’ rhetoric of shared benefit for “all of
us,” participation in PMI research can more closely
resemble altruism: donating data without direct insur-
ance (literally) that the benefits will reach the partici-
pant (Sabatello and Appelbaum 2017).
By treating patients’ concerns over inequitable access as
a “spillover” effect of general mistrust in the health care
system or health care providers, Kraft and colleagues frame
these concerns as matters of “personal and familial experi-
ence” or as relational issues, rather than systematic institu-
tional problems extending to research endeavors. Yet
because systemic inequities both characterize the U.S.
health care system and extend to the distribution of benefits
from programs like the PMI, this unnecessarily trivializes or
characterizes as misplaced what are in fact legitimate con-
cerns about wider societal inequalities, closing off possibili-
ties for a more critical approach to “precision medicine.”
Despite their valuable contribution to understanding
factors influencing trust in systems medicine research,
Kraft and colleagues presume and at times reproduce,
rather than critically engage with or even fully acknowl-
edge, the underlying contextual and value-laden dis-
courses and agendas that structure “precision medicine”
in the United States. The multiple labels and related termi-
nological debate reflect competing agendas relating to
what systems approaches can and should enable, what the
future of medicine should look like, and thus where invest-
ment should be directed. The choice of the “precision”
term and related rhetoric to carry these hopes and invest-
ment reflects the broader American political and health
care context. By not critically engaging with the ethically
and politically loaded discourses within which the
“precision medicine” terminology and related language is
embedded, Kraft and colleagues, even if unwittingly, over-
look (at best) and reproduce (at worst) these discourses in
ways that legitimate them. As well as considering “the his-
tories and cultural perspectives of diverse patients,” to
understand what promotes trust and constitutes trustwor-
thiness in research, we must contextualize the research
itself and account for the wider socioeconomic and politi-
cal histories through which these perspectives are formed.
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